文献速递主动脉疾病

顺应性支架作为钝性胸主动脉损伤TEVAR标准治疗

Conformable Endograft as a Standard Treatment for Thoracic Endovascular Aortic Repair in Patients With Blunt Thoracic Aortic Injury.
PubMed 文献 · J Endovasc Ther · 2026-03-19

该回顾性单中心研究纳入57例钝性胸主动脉损伤行TEVAR的患者,比较顺应性支架(Gore cTAG,30例)与非顺应性支架(27例)的结局。顺应性支架组1、3、5年主动脉相关免再干预生存率分别为100%、100%、96.7%,显著优于非顺应性支架组的81.4%、81.4%、77.7%(p=0.03)。研究表明按解剖选择顺应性支架可能改善预后,鸟嘴征常见但与不良结局无关。

要点

  • 顺应性支架组主动脉相关免再干预生存率显著优于非顺应性支架组(p=0.03)。
  • 非顺应性支架组出现2例术后Ia型内漏和3例II型内漏。
  • 鸟嘴征在两组均常见,且与不良结局无关。

核心结论

  • 在按解剖正确选择的前提下,Gore cTAG顺应性支架用于BTAI患者TEVAR后结局似乎优于非顺应性支架。
  • 鸟嘴征在两组中均频繁出现,但未与不良结局相关。

研究设计与样本

  • 回顾性研究,纳入2001年6月至2019年5月在一家三级血管中心因BTAI接受TEVAR的全部57例患者(50例男性,平均年龄37.3岁)。
  • 按支架类型分为两组:顺应性支架组(Gore cTAG)30例(52.6%),非顺应性支架组27例(47.4%)。
  • 主要终点为主动脉相关免再干预生存,次要终点包括30天院内死亡率、术后并发症和影像学发现。

主要发现

  • 顺应性支架组1年、3年、5年主动脉相关免再干预生存率分别为100%、100%、96.7%,非顺应性支架组分别为81.4%、81.4%、77.7%(p=0.03)。
  • 非顺应性支架组观察到2例术后Ia型内漏和3例术后II型内漏。
  • 鸟嘴征在非顺应性支架组更常见(70.4% vs 53.3,p=0.32)。

临床怎么用

  • 对于BTAI患者行TEVAR时,可根据主动脉解剖选择性使用顺应性支架(Gore cTAG)以改善主动脉相关免再干预生存。
  • 术后鸟嘴征常见,但不应仅凭此征象判断预后不良。

局限性

  • 研究为小样本回顾性队列,结论需进一步研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A consensus exists among vascular surgery societies that blunt thoracic aortic injury (BTAI) should be treated with thoracic endovascular aortic repair (TEVAR) in patients with favorable aortic anatomy. However, selecting the correct landing zones and endograft sizing remains challenging in patients with BTAI. To overcome these limitations, conformable endografts are often used for TEVAR, even in patients with BTAI. This study aimed to analyze the outcomes of these patients with respect to anatomical and technical factors. METHODS: This retrospective study included all patients with BTAI who underwent TEVAR at a tertiary vascular center. The primary endpoint was aortic-related reintervention-free survival. Secondary endpoints were 30-day in-hospital mortality, postoperative complications, and radiological findings. Patients were divided into 2 groups: group 1, patients with a conformable endograft (cTAG Gore), and group 2, patients with a nonconformable endograft. RESULTS: Between June 2001 and May 2019, 57 patients (50 men; mean age, 37.3 years) with BTAI received 30 (52.6%) conformable (Gore cTAG) and 27 (47.4%) nonconformable endografts. The 1-, 3-, and 5-year aortic-related reintervention-free survival was 100%, 100%, and 96.7% in group 1 and 81.4%, 81.4%, and 77.7% in group 2, respectively (p=0.03). Two postoperative type Ia endoleaks and 3 postoperative type II endoleaks were observed in group 2. The bird beak sign was noted more often in group 2 (70.4% vs 53.3, p=0.32). CONCLUSIONS: This study, in a small cohort of patients, demonstrated that the Gore cTAG, when properly selected according to the patient's anatomy, appears to provide better outcomes after TEVAR for patients with BTAI than nonconformable devices. A bird beak sign occurred frequently in both groups and were not associated with poor outcomes. Further studies are required to confirm these findings.Clinical ImpactThis study in a small cohort of patients demonstrated that the Gore cTAG endoprosthesis, when properly selected to match the patient's anatomy, appears to result in better outcomes after TEVAR in patients with BTAI than nonconformable devices. In addition, the BBS was common in both groups of patients and was not associated with a worse outcome.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Kukulski L, Pfister K, Sachsamanis G, et al. Conformable Endograft as a Standard Treatment for Thoracic Endovascular Aortic Repair in Patients With Blunt Thoracic Aortic Injury. J Endovasc Ther. 2026. PMID: 41852071. doi:10.1177/15266028261423521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。